Literature DB >> 6231256

The effects of beta 1-adrenoceptor partial agonist ICI 118.587 on left ventricular function in patients with coronary heart disease.

M J Ikäheimo, J T Takkunen.   

Abstract

We investigated the effects of a new selective beta 1-adrenoceptor partial agonist, ICI 118.587, on left ventricular function in 14 patients with coronary heart disease and a history of stable angina pectoris. The drug (0.2 mg/kg) increased peak left ventricular dp/dt from 1518 to 1993 mm Hg/sec (P less than 0.001) and left ventricular Vmax from 1.63 to 2.08 circ/sec (P less than 0.001), while left ventricular end-diastolic pressure decreased (P less than 0.05). Measured by echocardiography, the fractional shortening of the left ventricular minor axis diameter and the mean velocity of the left ventricular circumferential fiber shortening increased (P less than 0.001) and the cardiac index increased by 36%, reflecting increased contractility mainly in the normal left ventricular wall areas. In coronary heart disease, ICI 118.587 increased left ventricular muscle contractility and output without untoward side effects in the majority of the patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6231256     DOI: 10.1016/0167-5273(84)90111-6

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  8 in total

Review 1.  Beta-adrenoceptor partial agonists: a renaissance in cardiovascular therapy?

Authors:  D G Waller
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

Review 2.  Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  R Furlong; R N Brogden
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

3.  Myocardial, coronary, and peripheral effects of xamoterol (ICI 118,587) in open-chest pigs.

Authors:  N Galiè; M Metalli; R Zannoli; G Binetti; A Branzi; B Magnani
Journal:  Cardiovasc Drugs Ther       Date:  1989-03       Impact factor: 3.727

4.  Digoxin and xamoterol in patients with moderate chronic heart failure. A double-blind, randomized, controlled study.

Authors:  E V Sorensen; B Sterndorff; M F Andersen; O Faergeman
Journal:  Cardiovasc Drugs Ther       Date:  1989-04       Impact factor: 3.727

5.  Effects of xamoterol on resting and exercise haemodynamics in patients with chronic heart failure.

Authors:  S J Virk; M K Davies
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

6.  Effects of xamoterol, a beta 1 adrenoceptor partial agonist, in patients with ischaemic dysfunction of the left ventricle.

Authors:  E Vigholt-Sørensen; O Faergeman; H M Snow
Journal:  Br Heart J       Date:  1989-11

7.  Electrophysiologic effects of intravenous xamoterol in patients with sinus node dysfunction.

Authors:  M de Marneffe; P Waterschoot; A Bernard; P Dubois; F Boujelben; I Liebens; M Englert
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

8.  The electrophysiological effects of intravenous xamoterol in man.

Authors:  R J Bowes; P C Gautam; D R Graham; A Harley
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.